ÂÜÀòÂÒÂ×

Markus Krieger has over 17 years of work experience in the biopharmaceutical industry. From 2004 to 2006, they worked as a Research Assistant at the Institute for Developmental Neurobiology, University of Heidelberg. Markus then moved on to the Interdisciplinary Center for Neurosciences, University of Heidelberg, where they were a M.Sc. Student and Research Assistant from 2006 to 2008. In 2008, they joined SYGNIS Bioscience GmbH & Co. KG as a Project Manager, Staff Scientist, and Ph.D. Student. During this time, they established the blood cytokine GM-CSF as a regulator of cognitive processing. In 2013, they joined Octapharma Biopharmaceuticals GmbH as a Project Manager, Deputy Head of Recombinant R&D, and graduated the Corporate "Talent Pool" Management Program. In this role, they delivered Nuwiq® to market in Europe, US & Japan, managed development projects for hematology products in three categories, ensured design and installation of AAV gene therapy lab and research platform, presented on-site at regulatory authorities in Europe and China, and explored & mapped project-relevant IP landscapes. Finally, in 2022, they joined CEVEC Pharmaceuticals GmbH as Vice President Technology Development.

Markus Krieger received their Doctor of Philosophy (Ph.D.) in Molecular Neuroscience from Heidelberg University in 2011. Prior to that, they obtained their Master of Science (M.Sc.) in Molecular Biology and Neurosciences from Heidelberg University in 2007. Markus also attended the University of Giessen from 2002 to 2003. Additionally, they hold certifications in Higher Business English (CEFR Level C2) from the University of Cambridge, ESOL Examinations, and in Project Management from the University of Washington School of Business.